Clinical Trials of Hepatitis B Immune Globulin

Authors:
  • DSD. Mac N. Surgenor
    D. Mac N. Surgenor
  • TCThomas C. Chalmers
    Thomas C. Chalmers
  • MCMarcel E. Conrad
    Marcel E. Conrad
  • WFWilliam T. Friedewald
    William T. Friedewald
  • GGGeorge F. Grady
    George F. Grady
  • MHMichael Hamilton
    Michael Hamilton
  • JMJames W. Mosley
    James W. Mosley
  • APAlfred M. Prince
    Alfred M. Prince
  • JSJames M. Stengle
    James M. Stengle

Abstract
Plasma from persons with high titers of hepatitis B antibody (anti-HBs) was used to manufacture one lot of hepatitis B "immune" globulin sufficient for four interlocking clinical trials of prevention or modification of hepatitis B infections. The trials were carried out in renal dialysis units, in medical personnel with accidental exposures to hepatitis B, in transfused patients, and in patients with fulminant hepatitis. A single policy board developed protocols that allowed comparisons among the four studies while respecting the unique requirements of each. (N Engl J Med 293: 1060–1062,1975)